{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T06:39:17Z","timestamp":1747204757299,"version":"3.40.5"},"posted":{"date-parts":[[2023,6,26]]},"group-title":"In Review","reference-count":71,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T00:00:00Z","timestamp":1687737600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,6,10]]},"abstract":"<title>Abstract<\/title>\n        <p>Malaria, caused by <italic>Plasmodium<\/italic> parasites, remains one of the most devastating infectious diseases worldwide, despite control efforts that have lowered morbidity and mortality. The only <italic>P. falciparum<\/italic> vaccine candidates to show field efficacy are those targeting the asymptomatic pre-erythrocytic (PE) stages of infection. The subunit (SU) RTS,S\/AS01 vaccine, the only licensed malaria vaccine to date, is only modestly effective against clinical malaria. Both RTS,S\/AS01 and the SU R21 vaccine candidate target the PE sporozoite (spz) circumsporozoite (CS) protein. These candidates elicit high-titer antibodies that provide short-term protection from disease, but do not induce the liver-resident memory CD8<sup>+<\/sup> T cells (Trm) that confer strong PE immunity and long-term protection. In contrast, whole-organism (WO) vaccines, employing for example radiation-attenuated spz (RAS), elicit both high antibody titers and Trm, and have achieved high levels of sterilizing protection. However, they require multiple intravenous (IV) doses, which must be administered at intervals of several weeks, complicating mass administration in the field. Moreover, the quantities of spz required present production difficulties. To reduce reliance on WO while maintaining protection via both antibodies and Trm responses, we have developed an accelerated vaccination regimen that combines two distinct agents in a prime-and-trap strategy. While the priming dose is a self-replicating RNA encoding <italic>P. yoelii<\/italic> CS protein, delivered via an advanced cationic nanocarrier (LION\u2122), the trapping dose consists of WO RAS. This accelerated regime confers sterile protection in the <italic>P. yoelii<\/italic> mouse model of malaria. Our approach presents a clear path to late-stage preclinical and clinical testing of dose-sparing, same-day regimens that can confer sterilizing protection against malaria.<\/p>","DOI":"10.21203\/rs.3.rs-3045076\/v1","type":"posted-content","created":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T20:20:57Z","timestamp":1687810857000},"source":"Crossref","is-referenced-by-count":1,"title":["Accelerated prime-and-trap vaccine regimen in mice using repRNA-based CSP malaria vaccine"],"prefix":"10.21203","author":[{"given":"Zachary","family":"MacMillen","sequence":"first","affiliation":[{"name":"MalarVx, Inc"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiara","family":"Hatzakis","sequence":"additional","affiliation":[{"name":"MalarVx, Inc"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Simpson","sequence":"additional","affiliation":[{"name":"HDT Bio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Shears","sequence":"additional","affiliation":[{"name":"UW"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felicia","family":"Watson","sequence":"additional","affiliation":[{"name":"UW"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesse","family":"Erasmus","sequence":"additional","affiliation":[{"name":"HDT Bio Corp"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Khandhar","sequence":"additional","affiliation":[{"name":"HDT Bio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandon","family":"Wilder","sequence":"additional","affiliation":[{"name":"OHSU"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2048-0131","authenticated-orcid":false,"given":"Sean","family":"Murphy","sequence":"additional","affiliation":[{"name":"University of Washington"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Reed","sequence":"additional","affiliation":[{"name":"Infectious Disease Research Institute"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Davie","sequence":"additional","affiliation":[{"name":"MalarVx, Inc"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3569-2049","authenticated-orcid":false,"given":"Marion","family":"AVRIL","sequence":"additional","affiliation":[{"name":"MalarVx, Inc"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"WHO | World malaria report 2018. WHO http:\/\/www.who.int\/malaria\/publications\/world-malaria-report-2018\/report\/en\/ (2020)."},{"key":"ref2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.chom.2018.06.008","article-title":"Malaria Vaccines: Recent Advances and New Horizons","volume":"24","author":"Draper SJ","year":"2018","unstructured":"Draper, S. J. et al. Malaria Vaccines: Recent Advances and New Horizons. Cell Host Microbe 24, 43 (2018).","journal-title":"Cell Host Microbe"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nature21060","article-title":"Sterile protection against human malaria by chemoattenuated PfSPZ vaccine","volume":"542","author":"Mordm\u00fcller B","year":"2017","unstructured":"Mordm\u00fcller, B. et al. Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature 542, 445\u2013449 (2017).","journal-title":"Nature"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"e1001685","DOI":"10.1371\/journal.pmed.1001685","article-title":"Efficacy and safety of the RTS,S\/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites","volume":"11","author":"RTS,S Clinical Trials Partnership","year":"2014","unstructured":"RTS,S Clinical Trials Partnership. Efficacy and safety of the RTS,S\/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med. 11, e1001685 (2014).","journal-title":"PLoS Med."},{"key":"ref5","doi-asserted-by":"crossref","first-page":"e61395","DOI":"10.1371\/journal.pone.0061395","article-title":"The relationship between RTS,S vaccine-induced antibodies, CD4+ T cell responses and protection against Plasmodium falciparum infection","volume":"8","author":"White MT","year":"2013","unstructured":"White, M. T. et al. The relationship between RTS,S vaccine-induced antibodies, CD4+ T cell responses and protection against Plasmodium falciparum infection. PloS One 8, e61395 (2013).","journal-title":"PloS One"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1056\/NEJMoa1208394","article-title":"A phase 3 trial of RTS,S\/AS01 malaria vaccine in African infants","volume":"367","author":"Clinical Trials RTS,S","year":"2012","unstructured":"RTS,S Clinical Trials Partnership et al. A phase 3 trial of RTS,S\/AS01 malaria vaccine in African infants. N. Engl. J. Med. 367, 2284\u20132295 (2012).","journal-title":"N. Engl. J. Med."},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1056\/NEJMoa1102287","article-title":"First results of phase 3 trial of RTS,S\/AS01 malaria vaccine in African children","volume":"365","author":"Clinical Trials RTS,S","year":"2011","unstructured":"RTS,S Clinical Trials Partnership et al. First results of phase 3 trial of RTS,S\/AS01 malaria vaccine in African children. N. Engl. J. Med. 365, 1863\u20131875 (2011).","journal-title":"N. Engl. J. Med."},{"key":"ref8","article-title":"low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial - PubMed","author":"Efficacy of a","year":"2021","unstructured":"Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/33964223\/ (2021)."},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1056\/NEJMoa1505819","article-title":"Genetic Diversity and Protective Efficacy of the RTS,S\/AS01 Malaria Vaccine","volume":"373","author":"Neafsey DE","year":"2015","unstructured":"Neafsey, D. E. et al. Genetic Diversity and Protective Efficacy of the RTS,S\/AS01 Malaria Vaccine. N. Engl. J. Med. 373, 2025\u20132037 (2015).","journal-title":"N. Engl. J. Med."},{"year":"2017","author":"Oyen D","key":"ref10","unstructured":"Oyen, D. et al. Structural basis for antibody recognition of the NANP repeats in Plasmodium falciparum circumsporozoite protein. Proc. Natl. Acad. Sci. U. S. A. 114, E10438\u2013E10445 (2017)."},{"key":"ref11","doi-asserted-by":"crossref","first-page":"46621","DOI":"10.1038\/srep46621","article-title":"V. S. Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine","volume":"7","author":"Collins KA","year":"2017","unstructured":"Collins, K. A., Snaith, R., Cottingham, M. G., Gilbert, S. C. & Hill, A. V. S. Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine. Sci. Rep. 7, 46621 (2017).","journal-title":"Sci. Rep."},{"key":"ref12","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12936-020-3141-z","article-title":"Plasmodium falciparum pre-erythrocytic stage vaccine development","volume":"19","author":"Molina-Franky J","year":"2020","unstructured":"Molina-Franky, J. et al. Plasmodium falciparum pre-erythrocytic stage vaccine development. Malar. J. 19, 56 (2020).","journal-title":"Malar. J."},{"key":"ref13","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1128\/IAI.00180-13","article-title":"Inducing humoral and cellular responses to multiple sporozoite and liver-stage malaria antigens using exogenous plasmid DNA","volume":"81","author":"Ferraro B","year":"2013","unstructured":"Ferraro, B. et al. Inducing humoral and cellular responses to multiple sporozoite and liver-stage malaria antigens using exogenous plasmid DNA. Infect. Immun. 81, 3709\u20133720 (2013).","journal-title":"Infect. Immun."},{"key":"ref14","doi-asserted-by":"crossref","first-page":"5448","DOI":"10.1016\/j.vaccine.2017.02.040","article-title":"Development of a self-assembling protein nanoparticle vaccine targeting Plasmodium falciparum Circumsporozoite Protein delivered in three Army Liposome Formulation adjuvants","volume":"35","author":"Seth L","year":"2017","unstructured":"Seth, L. et al. Development of a self-assembling protein nanoparticle vaccine targeting Plasmodium falciparum Circumsporozoite Protein delivered in three Army Liposome Formulation adjuvants. Vaccine 35, 5448\u20135454 (2017).","journal-title":"Vaccine"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"e1010133","DOI":"10.1371\/journal.ppat.1010133","article-title":"Protective effects of combining monoclonal antibodies and vaccines against the Plasmodium falciparum circumsporozoite protein","volume":"17","author":"Wang LT","year":"2021","unstructured":"Wang, L. T. et al. Protective effects of combining monoclonal antibodies and vaccines against the Plasmodium falciparum circumsporozoite protein. PLoS Pathog. 17, e1010133 (2021).","journal-title":"PLoS Pathog."},{"key":"ref16","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.immuni.2020.08.014","article-title":"A Potent Anti-Malarial Human Monoclonal Antibody Targets Circumsporozoite Protein Minor Repeats and Neutralizes Sporozoites in the Liver","volume":"53","author":"Wang LT","year":"2020","unstructured":"Wang, L. T. et al. A Potent Anti-Malarial Human Monoclonal Antibody Targets Circumsporozoite Protein Minor Repeats and Neutralizes Sporozoites in the Liver. Immunity 53, 733\u2013744.e8 (2020).","journal-title":"Immunity"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12936-020-03181-0","article-title":"Characterization of two in vivo challenge models to measure functional activity of monoclonal antibodies to Plasmodium falciparum circumsporozoite protein","volume":"19","author":"Raghunandan R","year":"2020","unstructured":"Raghunandan, R. et al. Characterization of two in vivo challenge models to measure functional activity of monoclonal antibodies to Plasmodium falciparum circumsporozoite protein. Malar. J. 19, 113 (2020).","journal-title":"Malar. J."},{"key":"ref18","first-page":"20","article-title":"Designer Parasites: Genetically Engineered Plasmodium as Vaccines To Prevent Malaria Infection","volume":"202","author":"Goswami D","year":"2019","unstructured":"Goswami, D., Minkah, N. K. & Kappe, S. H. I. Designer Parasites: Genetically Engineered Plasmodium as Vaccines To Prevent Malaria Infection. J. Immunol. Baltim. Md 1950 202, 20\u201328 (2019).","journal-title":"J. Immunol. Baltim. Md 1950"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"109956","DOI":"10.1016\/j.celrep.2021.109956","article-title":"Expeditious recruitment of circulating memory CD8 T cells to the liver facilitates control of malaria","volume":"37","author":"Lefebvre MN","year":"2021","unstructured":"Lefebvre, M. N. et al. Expeditious recruitment of circulating memory CD8 T cells to the liver facilitates control of malaria. Cell Rep. 37, 109956 (2021).","journal-title":"Cell Rep."},{"author":"Hassert M","key":"ref20","unstructured":"Hassert, M., Arumugam, S. & Harty, J. T. Memory CD8 + T cell-mediated protection against liver-stage malaria. Immunol. Rev. n\/a,."},{"key":"ref21","first-page":"272","article-title":"CD8 T-cell-mediated protection against liver-stage malaria: lessons from a mouse model","volume":"5","author":"Braeckel-Budimir N","year":"2014","unstructured":"Van Braeckel-Budimir, N. & Harty, J. T. CD8 T-cell-mediated protection against liver-stage malaria: lessons from a mouse model. Front. Microbiol. 5, 272 (2014).","journal-title":"Front. Microbiol."},{"key":"ref22","doi-asserted-by":"crossref","first-page":"e89154","DOI":"10.1172\/jci.insight.89154","article-title":"Protection against Plasmodium falciparum malaria by PfSPZ Vaccine","volume":"2","author":"Epstein JE","year":"2017","unstructured":"Epstein, J. E. et al. Protection against Plasmodium falciparum malaria by PfSPZ Vaccine. JCI Insight 2, e89154 (2017).","journal-title":"JCI Insight"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"338","DOI":"10.4269\/ajtmh.17-1014","article-title":"Safety, Immunogenicity, and Protective Efficacy against Controlled Human Malaria Infection of Plasmodium falciparum Sporozoite Vaccine in Tanzanian Adults","volume":"99","author":"Jongo SA","year":"2018","unstructured":"Jongo, S. A. et al. Safety, Immunogenicity, and Protective Efficacy against Controlled Human Malaria Infection of Plasmodium falciparum Sporozoite Vaccine in Tanzanian Adults. Am. J. Trop. Med. Hyg. 99, 338\u2013349 (2018).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref24","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-021-03684-z","article-title":"Two chemoattenuated PfSPZ malaria vaccines induce sterile hepatic immunity","volume":"595","author":"Mwakingwe-Omari A","year":"2021","unstructured":"Mwakingwe-Omari, A. et al. Two chemoattenuated PfSPZ malaria vaccines induce sterile hepatic immunity. Nature 595, 289\u2013294 (2021).","journal-title":"Nature"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"eabn9709","DOI":"10.1126\/scitranslmed.abn9709","article-title":"A genetically engineered Plasmodium falciparum parasite vaccine provides protection from controlled human malaria infection","volume":"14","author":"Murphy SC","year":"2022","unstructured":"Murphy, S. C. et al. A genetically engineered Plasmodium falciparum parasite vaccine provides protection from controlled human malaria infection. Sci. Transl. Med. 14, eabn9709 (2022).","journal-title":"Sci. Transl. Med."},{"key":"ref26","doi-asserted-by":"crossref","first-page":"eaad9099","DOI":"10.1126\/scitranslmed.aad9099","article-title":"Complete attenuation of genetically engineered Plasmodium falciparum sporozoites in human subjects","volume":"9","author":"Kublin JG","year":"2017","unstructured":"Kublin, J. G. et al. Complete attenuation of genetically engineered Plasmodium falciparum sporozoites in human subjects. Sci. Transl. Med. 9, eaad9099 (2017).","journal-title":"Sci. Transl. Med."},{"key":"ref27","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/nm.4110","article-title":"Protection against malaria at 1 year and immune correlates following PfSPZ vaccination","volume":"22","author":"Ishizuka AS","year":"2016","unstructured":"Ishizuka, A. S. et al. Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nat. Med. 22, 614\u2013623 (2016).","journal-title":"Nat. Med."},{"key":"ref28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02748","article-title":"The Development of Whole Sporozoite Vaccines for Plasmodium falciparum Malaria","volume":"9","author":"Itsara LS","year":"2018","unstructured":"Itsara, L. S. et al. The Development of Whole Sporozoite Vaccines for Plasmodium falciparum Malaria. Front. Immunol. 9, (2018).","journal-title":"Front. Immunol."},{"key":"ref29","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S1473-3099(17)30104-4","article-title":"Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial","volume":"17","author":"Sissoko MS","year":"2017","unstructured":"Sissoko, M. S. et al. Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. Lancet Infect. Dis. 17, 498\u2013509 (2017).","journal-title":"Lancet Infect. Dis."},{"key":"ref30","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S1473-3099(21)00332-7","article-title":"Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial","volume":"22","author":"Sissoko MS","year":"2022","unstructured":"Sissoko, M. S. et al. Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial. Lancet Infect. Dis. 22, 377\u2013389 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"ref31","doi-asserted-by":"crossref","first-page":"101579","DOI":"10.1016\/j.eclinm.2022.101579","article-title":"PfSPZ-CVac malaria vaccine demonstrates safety among malaria-experienced adults: A randomized, controlled phase 1 trial","volume":"52","author":"Coulibaly D","year":"2022","unstructured":"Coulibaly, D. et al. PfSPZ-CVac malaria vaccine demonstrates safety among malaria-experienced adults: A randomized, controlled phase 1 trial. EClinicalMedicine 52, 101579 (2022).","journal-title":"EClinicalMedicine"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nri1746","article-title":"Pre-erythrocytic malaria vaccines: towards greater efficacy","volume":"6","author":"Hill AVS","year":"2006","unstructured":"Hill, A. V. S. Pre-erythrocytic malaria vaccines: towards greater efficacy. Nat. Rev. Immunol. 6, 21\u201332 (2006).","journal-title":"Nat. Rev. Immunol."},{"key":"ref33","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.immuni.2019.09.019","article-title":"Liver-Resident Memory CD8 + T Cells Form a Front-Line Defense against Malaria Liver-Stage Infection","volume":"51","author":"Fernandez-Ruiz D","year":"2019","unstructured":"Fernandez-Ruiz, D. et al. Liver-Resident Memory CD8 + T Cells Form a Front-Line Defense against Malaria Liver-Stage Infection. Immunity 51, 780 (2019).","journal-title":"Immunity"},{"key":"ref34","first-page":"1984","article-title":"Prime-and-Trap Malaria Vaccination To Generate Protective CD8 + Liver-Resident Memory T Cells","volume":"201","author":"Olsen TM","year":"2018","unstructured":"Olsen, T. M., Stone, B. C., Chuenchob, V. & Murphy, S. C. Prime-and-Trap Malaria Vaccination To Generate Protective CD8 + Liver-Resident Memory T Cells. J. Immunol. Baltim. Md 1950 201, 1984\u20131993 (2018).","journal-title":"J. Immunol. Baltim. Md 1950"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.21-1084","article-title":"Cryopreserved Sporozoites with and without the Glycolipid Adjuvant 7DW8-5 Protect in Prime-and-Trap Malaria Vaccination","volume":"tpmd211084","author":"Watson F","year":"2022","unstructured":"Watson, F. et al. Cryopreserved Sporozoites with and without the Glycolipid Adjuvant 7DW8-5 Protect in Prime-and-Trap Malaria Vaccination. Am. J. Trop. Med. Hyg. tpmd211084 (2022) doi:10.4269\/ajtmh.21-1084.","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref36","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41541-021-00345-0","article-title":"Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice","volume":"6","author":"Mallory KL","year":"2021","unstructured":"Mallory, K. L. et al. Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice. NPJ Vaccines 6, 84 (2021).","journal-title":"NPJ Vaccines"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41541-022-00577-8","article-title":"mRNA-LNP expressing PfCSP and Pfs25 vaccine candidates targeting infection and transmission of Plasmodium falciparum","volume":"7","author":"Hayashi CTH","year":"2022","unstructured":"Hayashi, C. T. H. et al. mRNA-LNP expressing PfCSP and Pfs25 vaccine candidates targeting infection and transmission of Plasmodium falciparum. NPJ Vaccines 7, 155 (2022).","journal-title":"NPJ Vaccines"},{"year":"2020","author":"The \u2018anti-","key":"ref38","unstructured":"The \u2018anti-hype\u2019 vaccine | Nature Biotechnology. https:\/\/www.nature.com\/articles\/nbt.3812 (2020)."},{"key":"ref39","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates","volume":"383","author":"Walsh EE","year":"2020","unstructured":"Walsh, E. E. et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N. Engl. J. Med. 383, 2439\u20132450 (2020).","journal-title":"N. Engl. J. Med."},{"key":"ref40","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden LR","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"ref41","unstructured":"spikevax-previously-covid-19-vaccine-moderna-epar-public-assessment-report_en.pdf."},{"key":"ref42","unstructured":"comirnaty-epar-public-assessment-report_en.pdf."},{"key":"ref43","first-page":"13","volume-title":"Advances in Genetics","author":"Zhao Y","year":"2014","unstructured":"Zhao, Y. & Huang, L. Chapter Two - Lipid Nanoparticles for Gene Delivery. in Advances in Genetics (eds. Huang, L., Liu, D. & Wagner, E.) vol.\u00a088 13\u201336 (Academic Press, 2014)."},{"key":"ref44","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc9396","article-title":"An Alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates","volume":"12","author":"Erasmus JH","year":"2020","unstructured":"Erasmus, J. H. et al. An Alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates. Sci. Transl. Med. 12, (2020).","journal-title":"Sci. Transl. Med."},{"key":"ref45","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1016\/j.ymthe.2018.07.010","article-title":"A Nanostructured Lipid Carrier for Delivery of a Replicating Viral RNA Provides Single, Low-Dose Protection against Zika","volume":"26","author":"Erasmus JH","year":"2018","unstructured":"Erasmus, J. H. et al. A Nanostructured Lipid Carrier for Delivery of a Replicating Viral RNA Provides Single, Low-Dose Protection against Zika. Mol. Ther. J. Am. Soc. Gene Ther. 26, 2507\u20132522 (2018).","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref46","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.omtm.2020.07.013","article-title":"Modified mRNA-LNP Vaccines Confer Protection against Experimental DENV-2 Infection in Mice","volume":"18","author":"Zhang M","year":"2020","unstructured":"Zhang, M., Sun, J., Li, M. & Jin, X. Modified mRNA-LNP Vaccines Confer Protection against Experimental DENV-2 Infection in Mice. Mol. Ther. - Methods Clin. Dev. 18, 702\u2013712 (2020).","journal-title":"Mol. Ther. - Methods Clin. Dev."},{"key":"ref47","unstructured":"COVID-19 shots with Seattle origins reach regulatory milestones in South Korea, India \u2013 GeekWire. https:\/\/www.geekwire.com\/2022\/covid-19-shots-with-seattle-origins-reach-regulatory-milestones-in-south-korea-india\/."},{"author":"Bio\u2019s HDT","key":"ref48","unstructured":"HDT Bio\u2019s COVID-19 Vaccine Wins Regulatory Approval in India | Business Wire. https:\/\/www.businesswire.com\/news\/home\/20220629005703\/en\/HDT-Bio%E2%80%99s-COVID-19-Vaccine-Wins-Regulatory-Approval-in-India."},{"key":"ref49","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1586\/14760584.2015.965690","article-title":"Self-replicating alphavirus RNA vaccines","volume":"14","author":"Ljungberg K","year":"2015","unstructured":"Ljungberg, K. & Liljestr\u00f6m, P. Self-replicating alphavirus RNA vaccines. Expert Rev. Vaccines 14, 177\u2013194 (2015).","journal-title":"Expert Rev. Vaccines"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"eaad9099","DOI":"10.1126\/scitranslmed.aad9099","article-title":"Complete attenuation of genetically engineered Plasmodium falciparum sporozoites in human subjects","volume":"9","author":"Kublin JG","year":"2017","unstructured":"Kublin, J. G. et al. Complete attenuation of genetically engineered Plasmodium falciparum sporozoites in human subjects. Sci. Transl. Med. 9, eaad9099 (2017).","journal-title":"Sci. Transl. Med."},{"key":"ref51","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.chom.2011.05.008","article-title":"Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites","volume":"9","author":"Butler NS","year":"2011","unstructured":"Butler, N. S. et al. Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites. Cell Host Microbe 9, 451\u2013462 (2011).","journal-title":"Cell Host Microbe"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1126\/science.1241800","article-title":"Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine","volume":"341","author":"Seder RA","year":"2013","unstructured":"Seder, R. A. et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 341, 1359\u20131365 (2013).","journal-title":"Science"},{"key":"ref53","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00088-18","article-title":"A Plasmodium Parasite with Complete Late Liver Stage Arrest Protects against Preerythrocytic and Erythrocytic Stage Infection in Mice","volume":"86","author":"Vaughan AM","year":"2018","unstructured":"Vaughan, A. M. et al. A Plasmodium Parasite with Complete Late Liver Stage Arrest Protects against Preerythrocytic and Erythrocytic Stage Infection in Mice. Infect. Immun. 86, (2018).","journal-title":"Infect. Immun."},{"key":"ref54","doi-asserted-by":"crossref","first-page":"135589","DOI":"10.1172\/jci.insight.135589","article-title":"A replication-competent late liver stage-attenuated human malaria parasite","volume":"5","author":"Goswami D","year":"2020","unstructured":"Goswami, D. et al. A replication-competent late liver stage-attenuated human malaria parasite. JCI Insight 5, 135589 (2020).","journal-title":"JCI Insight"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1086\/597121","article-title":"Vaccine-like immunity against malaria by repeated causal-prophylactic treatment of liver-stage Plasmodium parasites","volume":"199","author":"Putrianti ED","year":"2009","unstructured":"Putrianti, E. D., Silvie, O., Kordes, M., Borrmann, S. & Matuschewski, K. Vaccine-like immunity against malaria by repeated causal-prophylactic treatment of liver-stage Plasmodium parasites. J. Infect. Dis. 199, 899\u2013903 (2009).","journal-title":"J. Infect. Dis."},{"key":"ref56","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/216160a0","article-title":"Protective immunity produced by the injection of x-irradiated sporozoites of plasmodium berghei","volume":"216","author":"Nussenzweig RS","year":"1967","unstructured":"Nussenzweig, R. S., Vanderberg, J., Most, H. & Orton, C. Protective immunity produced by the injection of x-irradiated sporozoites of plasmodium berghei. Nature 216, 160\u2013162 (1967).","journal-title":"Nature"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/00000441-197309000-00002","article-title":"Immunization of man against sporozite-induced falciparum malaria","volume":"266","author":"Clyde DF","year":"1973","unstructured":"Clyde, D. F., Most, H., McCarthy, V. C. & Vanderberg, J. P. Immunization of man against sporozite-induced falciparum malaria. Am. J. Med. Sci. 266, 169\u2013177 (1973).","journal-title":"Am. J. Med. Sci."},{"year":"2005","author":"Mueller A-K","key":"ref58","unstructured":"Mueller, A.-K. et al. Plasmodium liver stage developmental arrest by depletion of a protein at the parasite-host interface. Proc. Natl. Acad. Sci. U. S. A. 102, 3022\u20133027 (2005)."},{"key":"ref59","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1093\/infdis\/jiu281","article-title":"The chemokine receptor CXCR6 is required for the maintenance of liver memory CD8+ T cells specific for infectious pathogens","volume":"210","author":"Tse S-W","year":"2014","unstructured":"Tse, S.-W., Radtke, A. J., Espinosa, D. A., Cockburn, I. A. & Zavala, F. The chemokine receptor CXCR6 is required for the maintenance of liver memory CD8+ T cells specific for infectious pathogens. J. Infect. Dis. 210, 1508\u20131516 (2014).","journal-title":"J. Infect. Dis."},{"issue":"Suppl 1","key":"ref60","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1590\/S0074-02762011000900022","article-title":"Induction and maintenance of protective CD8 + T cells against malaria liver stages: implications for vaccine development","volume":"106","author":"Tse S-W","year":"2011","unstructured":"Tse, S.-W., Radtke, A. J. & Zavala, F. Induction and maintenance of protective CD8 + T cells against malaria liver stages: implications for vaccine development. Mem. Inst. Oswaldo Cruz 106 Suppl 1, 172\u2013178 (2011).","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/gene.2013.20","article-title":"Unique transcriptional profile of liver-resident memory CD8 + T cells induced by immunization with malaria sporozoites","volume":"14","author":"Tse S-W","year":"2013","unstructured":"Tse, S.-W., Cockburn, I. A., Zhang, H., Scott, A. L. & Zavala, F. Unique transcriptional profile of liver-resident memory CD8 + T cells induced by immunization with malaria sporozoites. Genes Immun. 14, 302\u2013309 (2013).","journal-title":"Genes Immun."},{"key":"ref62","doi-asserted-by":"crossref","first-page":"e65960","DOI":"10.1371\/journal.pone.0065960","article-title":"Optimising Controlled Human Malaria Infection Studies Using Cryopreserved P. falciparum Parasites Administered by Needle and Syringe","volume":"8","author":"Sheehy SH","year":"2013","unstructured":"Sheehy, S. H. et al. Optimising Controlled Human Malaria Infection Studies Using Cryopreserved P. falciparum Parasites Administered by Needle and Syringe. PloS One 8, e65960 (2013).","journal-title":"PloS One"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.21-1297","article-title":"Safety, Tolerability, and Parasite Clearance Kinetics in Controlled Human Malaria Infection after Direct Venous Inoculation of Plasmodium falciparum Sporozoites: A Model for Evaluating New Blood-Stage Antimalarial Drugs","volume":"tpmd211297","author":"Chughlay MF","year":"2022","unstructured":"Chughlay, M. F. et al. Safety, Tolerability, and Parasite Clearance Kinetics in Controlled Human Malaria Infection after Direct Venous Inoculation of Plasmodium falciparum Sporozoites: A Model for Evaluating New Blood-Stage Antimalarial Drugs. Am. J. Trop. Med. Hyg. tpmd211297 (2022) doi:10.4269\/ajtmh.21-1297.","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref64","doi-asserted-by":"crossref","first-page":"338","DOI":"10.4269\/ajtmh.17-1014","article-title":"Safety, Immunogenicity, and Protective Efficacy against Controlled Human Malaria Infection of Plasmodium falciparum Sporozoite Vaccine in Tanzanian Adults","volume":"99","author":"Jongo SA","year":"2018","unstructured":"Jongo, S. A. et al. Safety, Immunogenicity, and Protective Efficacy against Controlled Human Malaria Infection of Plasmodium falciparum Sporozoite Vaccine in Tanzanian Adults. Am. J. Trop. Med. Hyg. 99, 338\u2013349 (2018).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref65","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41591-021-01470-y","article-title":"Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial","volume":"27","author":"Oneko M","year":"2021","unstructured":"Oneko, M. et al. Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial. Nat. Med. 27, 1636\u20131645 (2021).","journal-title":"Nat. Med."},{"key":"ref66","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/nature05361","article-title":"The circumsporozoite protein is an immunodominant protective antigen in irradiated sporozoites","volume":"444","author":"Kumar KA","year":"2006","unstructured":"Kumar, K. A. et al. The circumsporozoite protein is an immunodominant protective antigen in irradiated sporozoites. Nature 444, 937\u2013940 (2006).","journal-title":"Nature"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack FP","year":"2020","unstructured":"Polack, F. P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"ref68","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/s42003-021-02441-2","article-title":"Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration","volume":"4","author":"Carrasco MJ","year":"2021","unstructured":"Carrasco, M. J. et al. Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration. Commun. Biol. 4, 956 (2021).","journal-title":"Commun. Biol."},{"key":"ref69","doi-asserted-by":"crossref","first-page":"104196","DOI":"10.1016\/j.ebiom.2022.104196","article-title":"Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in na\u00efve hamsters compared to ancestral vaccine","volume":"83","author":"Hawman DW","year":"2022","unstructured":"Hawman, D. W. et al. Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in na\u00efve hamsters compared to ancestral vaccine. EBioMedicine 83, 104196 (2022).","journal-title":"EBioMedicine"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1086\/519742","article-title":"Protracted sterile protection with Plasmodium yoelii pre-erythrocytic genetically attenuated parasite malaria vaccines is independent of significant liver-stage persistence and is mediated by CD8 + T cells","volume":"196","author":"Tarun AS","year":"2007","unstructured":"Tarun, A. S. et al. Protracted sterile protection with Plasmodium yoelii pre-erythrocytic genetically attenuated parasite malaria vaccines is independent of significant liver-stage persistence and is mediated by CD8 + T cells. J. Infect. Dis. 196, 608\u2013616 (2007).","journal-title":"J. Infect. Dis."},{"key":"ref71","doi-asserted-by":"crossref","first-page":"3950","DOI":"10.1038\/s41467-019-11819-0","article-title":"Innate immunity limits protective adaptive immune responses against pre-erythrocytic malaria parasites","volume":"10","author":"Minkah NK","year":"2019","unstructured":"Minkah, N. K. et al. Innate immunity limits protective adaptive immune responses against pre-erythrocytic malaria parasites. Nat. Commun. 10, 3950 (2019).","journal-title":"Nat. Commun."}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3045076\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3045076\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T08:19:19Z","timestamp":1704961159000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3045076\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,26]]},"references-count":71,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-3045076\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1038\/s41541-023-00799-4","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2023,6,26]]},"subtype":"preprint"}}